Background : Although proton pump inhibitors (PPI) and H 2 -receptor antagonists (H 2 -RA) are routinely used in the treatment of reflux esophagitis (RE), no consensus has been reached yet as to whether the first-choice drug should be PPI or H 2 -RA. In this study, the effects of omeprazole (OMP) and famotidine (FAM) on RE have been examined in a randomized comparative study. Methods : Protocols of OMP 20 mg once daily or FAM 20 mg twice daily for 8 weeks were allocated to 56 cases with RE at random, using an envelope randomization method. Their efficacy in achieving healing was examined endoscopically and a relief from subjective symptoms was compared. Results : Patient's background such as sex, age, recurrence, hiatal hernia, smoking and drinking habits, and complications, and the severity of esophagitis at the time of enrolment were not significantly different between the two groups. Healing in the OMP group and the FAM group was observed in 72 and 32% ( P = 0.025) of patients at week 4 and 95 and 53% ( P = 0.003) of patients at week 8, respectively. Subjective symptoms were relieved more frequently in the OMP group (at week 2, 67% compared with 29%, P = 0.005; at week 4, 95% compared with 55%, P = 0.009), but this superiority was not significant at week 8 (94% compared with 65%, P = 0.085). No serious adverse events occurred. Conclusions : Omeprazole provided quicker healing and a greater relief from subjective symptoms than did FAM in the treatment of RE, and was considered more suitable as a first-choice drug.
INTRODUCTION
Reflux esophagitis (RE) is considered to increase with age and has been common in well-developed countries, whereas it is relatively uncommon in Japan. In recent years, however, concerns over an increasing trend in RE have arisen in Japan, as many elderly people have been shown to maintain high levels of acid secretion capacity, 1 in addition to the fact that the elderly population has been increasing because of the improvement in life expectancy. The incidence of RE in Japan ranges from 5.2% in 2278 cases 2 to 16.3% in 6010 subjects. 3 Recently, attention has been drawn to the relationship between RE and Helicobacter pylori ( H. pylori ).
Generally, H. pylori infection is not commonly observed in patients with RE. 4, 5 However, an increased incidence of RE provoked by H. pylori eradication therapy has been reported. 6 Moreover, as H. pylori infection rates increase with age in Japan, 7 it is anticipated that the incidence of RE will increase further in the future in Japan.
The inhibition of acid secretion is very effective in treating RE. 8 This treatment approach uses proton pump inhibitors (PPI) or H 2 -receptor antagonists (H 2 -RA) as the first-choice drug, occasionally in combination with a pro-kinetics drug. In Japan, no consensus has been reached yet on whether the first-choice drug should be PPI or H 2 -RA. From the point of view of quality of life, prompt healing and a rapid relief from subjective symptoms are important in the treatment of RE. However, few studies have been done in Japan as to how effective PPI and H 2 -RA are in treating patients with RE in terms of obtaining healing and a relief from symptoms. In addition, whereas no dysplasia or neoplasms were observed after long-term omeprazole (OMP) (Omepral ® ; Astra Zeneca KK, Osaka, Japan) therapy up to 11 years, 8 patients with H. pylori infection developed atrophic gastritis significantly after the treatment with OMP for RE. 9 Therefore, the benefits of using potent acid suppressants for RE as well as any adverse consequences should be considered. In the present randomized comparative study, the efficacy of OMP and famotidine (FAM) (Gaster ® ; Yamanouchi Pharmaceutical Co. Ltd, Tokyo, Japan) in treating patients with RE was investigated. Omeprazole provided healing of esophagitis and alleviation of subjective symptoms significantly faster than did FAM, without severe adverse incidents.
METHODS

Subjects and protocols
Patients were diagnosed endoscopically as having RE (Los Angeles (LA) Classification, 10 Grade A to D). Patients who had the following background and complications were excluded from enrolment, if they: were under 20 years old; had serious complications such as hepatic, renal and cardiac diseases; had indications for surgery; had gastric ulcer; had duodenal ulcer and acute gastric mucosal lesion; had a history of digestive tract resection or vagotomy; were pregnant or possibly pregnant women; or had a drug allergy.
Omeprazole (OMP) and FAM were used. Patients were allocated to either the OMP group or the FAM group at random by an envelope randomization method. Omeprazole (OMP) 20 mg tablet was administered once daily and FAM 20 mg tablet was administered twice daily for 8 weeks in each group.
Observation parameters and assessment methods
Sex, age, history of esophagitis, smoking and drinking habits, concomitant disorders such as diabetes and hypertension, and esophageal hiatal hernia were examined as patients' background factors. The presence or absence of H. pylori infection was examined in 15 cases. Endoscopy was performed before and 4 and 8 weeks after treatment. The severity of RE was assessed according to the LA Classification. 'Healing' was defined as endoscopic observation of no mucosal break. The subjects were questioned before and at weeks 2, 4, and 8 of treatment on the symptoms of RE (heartburn, epigastralgia, acid belching, dysphagia, nausea, and vomiting). The severity and frequency of symptoms were scored according to the following criteria described by Vigneri et al . 11 Symptom severity Total scores for individual symptoms were calculated as an addition of the scores of symptom severity and frequency. 'Relief' from symptoms was defined as the status with the symptom score of zero. Adverse events were primarily checked by symptoms. Blood examination and urinalysis were performed before and after drug administration. The protocol was approved by the ethics committee of each institution and written informed consent was obtained from all patients.
Symptom frequency
Statistical analysis
Biases in the background of patients between the groups were tested with Fisher's exact probability test and unpaired t -test. Differences between the groups in endoscopic healing rates of RE and disappearance of symptoms were tested with Fisher's exact probability test. Differences in the symptom scores before and after drug administration, and also between the groups, were tested with Wilcoxon's signed rank test and Wilcoxon's rank sum test, respectively. A P -value of < 0.05 was considered to be significant.
RESULTS
Patients' background
A total of 56 patients (OMP group, 29; FAM group, 27) enrolled in the study. Five cases in the OMP group and four cases in the FAM group dropped out as a result of failure of follow up. Table 1 shows the patients' background. At the enrolment, the severity of RE was assessed: grade A, four cases (17%); grade B, 13 cases (54%); grade C, four cases (17%); and grade D, three cases (13%) in the OMP group. In the FAM group, there were grade A, nine cases (39%); grade B, nine cases (39%); grade C, three cases (13%); and grade D, two cases (9%). No significant difference between the two groups was observed in the distribution of severity as well as subjective symptom scores before the treatment.
Esophageal hiatal hernia was found in 15 cases in the OMP group and 13 cases in the FAM group (difference, not significant). No significant difference was observed between the two groups in: the numbers of cases with a history of esophagitis, sex, age, concomitant disorders, and smoking and drinking status. Figure 1 shows the cumulative healing rate of RE examined by endoscopy. The healing rates were 72% in the OMP group and 32% in the FAM group at week 4 and 95 and 53% at week 8, respectively. Healing was obtained significantly more frequently in the OMP group than in the FAM group at both weeks 4 and 8 ( P = 0.025 and P = 0.003, respectively). Changes in the severity of RE are shown in Tables 2 and 3 . In the OMP group, all cases achieved healing at week 8 except for one of the three grade D cases. In the FAM group, one case of grade D and two of the three grade C cases remained unhealed at week 8, indicating that cases with severe esophagitis are resistant to this treatment. 
Healing of reflux esophagitis
Relief from symptoms
A relief from symptoms was obtained more frequently in the OMP group than in the FAM group at weeks 2 and 4 (shown in Fig. 2 : week 2, 67% compared with 29%, P = 0.005; week 4, 95% compared with 55%, P = 0.009). Disappearance of symptoms was found more frequently in the OMP group than in the FAM group at week 8, but the difference was not significant (94% compared with 65%, P = 0.085).
Adverse events
Mild adverse events were observed in two cases (nausea, palpitation) in the OMP group and one case (abdominal pain) in the FAM group. All symptoms disappeared after cessation of the medication. Although the abnormal values were found in one case (GOT elevation: 22 → 39 IU/L and GPT elevation: 26 → 41 IU/L) in the OMP group and in two cases (total bilirubin: 1.0 → 1.3 mg/dL in one patient and γ -GTP:
28 → 64 mU/mL in another), drug administration was continued until the completion of the protocol without further increase of these values.
DISCUSSION
Subjective symptoms of RE do not correlate with endoscopic findings, 2, 12 and patients are often apprehensive about recurrence after discontinuation of therapy. Consequently, the quality of life of patients is greatly impaired unless they are free from symptoms. In this regard, it is desirable to achieve a rapid relief from symptoms. Proton pump inhibitor therapy has been shown to be effective in achieving a rapid relief from symptoms and healing of RE. The use of PPI is recommended in the 1995 'Guideline for the Diagnosis and Treatment of Reflux Esophagitis' in the USA. 13 Furthermore, ' Step Down Therapy' starting treatment with a PPI is recommended as initial stage therapeutic strategy in the Genval Workshop 'GERD Guideline'.
14 These guidelines are endorsed by the fact that rapid healing and relief from symptoms, as well as inhibition of after-meal acid secretion, can be obtained more frequently by PPI therapy than by H 2 -RA therapy. 11, 12, 15 A meta-analysis based on 43 published articles regarding PPI and H 2 -RA efficacy in healing RE in 7635 cases showed that PPI provided faster healing and relief from symptoms. 16 However, few clinical comparative studies have been performed in Japan for a comparison of PPI and H 2 -RA for healing RE. Soga et al. reported that healing rates of lower-grade RE at week 8 were 97% for OMP and 59% for FAM, respectively, 17 and concluded that OMP should be the first-choice drug for healing RE. Conversely, Umeda et al. reported that endoscopic grades of RE were not significantly different between lansoprazole (LPZ)-treated and FAM-treated groups after a 4-week treatment, although LPZ showed a higher improvement rate. 18 The excellent symptom improvement obtained by PPI is assumed to be a result of 24 h acid secretion control confirmed by pH monitoring. 12, 19 In the present study, 95% of the OMP group was relieved from symptoms at week 4, despite the fact that only 72% of the OMP group achieved healing diagnosed by endoscopy at the same time. This discrepancy indicates that even after symptoms disappear, OMP 
*Denotes cases with no mucosal break. 
*Denotes cases with no mucosal break. treatment should be continued at least for 8 weeks to heal the impaired mucosa, irrespective of the alleviation of the symptoms. Therefore, these results underscore the effectiveness of potent acid suppression to improve the quality of life of patients by ameliorating the grade of esophagitis, even when healing is not yet obtained.
This discrepancy was also recognized in the FAM group, and relief from symptoms preceded healing. However, FAM could not relieve symptoms as quickly as OMP, which reiterated the superiority of OMP to FAM. In the treatment of grade A esophagitis, all four cases were healed by OMP, but three of eight cases remained at the same grade when treated by FAM in the present study. Furthermore, severe cases (grade C and D) could achieve healing in only one of four cases treated by FAM, in contrast with the success of three of four cases treated by OMP. These results indicate that OMP is more effective not only in mild cases, but also severe cases.
Helicobacter pylori infection was observed in 25% of eight cases in the OMP group and in 86% of seven cases in the FAM group (data not shown), and the FAM group had a significantly higher rate of H. pylori infection (chi-squared test, P = 0.04). Reflux esophagitis patients not infected with H. pylori retain a higher acid secretion capacity than those infected with H. pylori. 4 Accordingly, the OMP group is presumed to have a higher acid secretion capacity and subsequently higher acidity in the esophagus. In addition, subjective symptom scores before the treatment were higher, although this was not significant, in the FAM group. Nevertheless, the OMP group achieved a significantly higher healing rate. This result corroborated the effectiveness of OMP again. In addition, the safety of OMP was comparable to that of FAM.
In conclusion, the present randomized trial demonstrated that OMP provided more rapid healing and higher incidence of relief from symptoms than FAM in the treatment of RE. Relief from symptoms preceded healing of the mucosa in both treatments. In the future, it is expected that H. pylori infection will be less prevalent, and RE will probably become more common in Japan. Thus, OMP, which is safe and effective, should be used actively as the first-line drug for RE.
